Premium
Disopyramide in the prevention of recurrence of atrial fibrillation after electroconversion
Author(s) -
Härtel G.,
Louhija A.,
Konttinen A.
Publication year - 1974
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1974156551
Subject(s) - disopyramide , atrial fibrillation , medicine , sinus rhythm , placebo , cardiology , anesthesia , clinical trial , double blind , alternative medicine , pathology
The effect of a new antidysrhythmic drug, disopyramide, was tested in a double‐blind clinical trial in 52 patients undergoing electroconversion of atrial fibrillation. During a 3 month follow‐up, the number of patients remaining in sinus rhythm after successful electroconversion was higher (p < 0.05) in the disopyramide group (72%) than in the placebo group (30%).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom